Search

Search bills, members, committees and pages...

S. 3019

U.S. SenateIn Senate Committee

Summary

S. 3019, the No Big Blockbuster Bailouts Act, was introduced in the Senate on Oct 21, 2025 by Sen. Peter Welch (D) with 2 co-sponsors. It was referred to Finance, and last saw action on Oct 21, 2025: Read twice and referred to the Committee on Finance.


Record

Text

S. 3019 has 2 co-sponsors.

sb3019/introduced-in-senate.txt
119 S3019 IS: No Big Blockbuster Bailouts Act
U.S. Senate
2025-10-21
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
II
119th CONGRESS
1st Session
S. 3019
IN THE SENATE OF THE UNITED STATES
October 21, 2025
Mr. Welch (for himself, Mr. Wyden , and Ms. Cortez
Masto ) introduced the following bill; which was read twice and
referred to the Committee on
Finance
A BILL
To amend title XI of the Social Security Act to provide for the treatment of
orphan drugs under the Medicare Drug Price Negotiation Program.
1.
Short title
This Act may be cited as the No Big Blockbuster Bailouts Act .
2.
Treatment of orphan drugs under the Medicare Drug Price Negotiation
Program
(a)
In general
Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended—
(1)
in paragraph (1), in the matter preceding subparagraph (A), by striking through (4) and inserting and (3) ;
(2)
in paragraph (3)—
(A)
by striking subparagraph (A);
(B)
by redesignating subparagraphs (B) and (C) as subparagraphs (A) and (B), respectively; and
(C)
in subparagraph (A)(iii), as redesignated by subparagraph (B) of this paragraph, by striking with respect to and inserting subject to paragraph (4), with respect to ; and
(3)
by striking paragraph (4) and inserting the following new paragraph:
(4)
Treatment of orphan drugs
In the case of a drug that is designated as a drug for one or more rare diseases or conditions and for which the only approved indication (or indications) is for one or more such rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act), paragraph (3)(A) shall be applied by substituting $400,000,000 for $200,000,000 in clause (i) of such paragraph.
.
(b)
Application
The amendments made by subsection (a) shall apply with respect to initial price applicability years (as defined in section 1191(b) of the Social Security Act ( 42 U.S.C. 1320f(b) )) beginning on or after January 1, 2028.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-10-21
  2. Passed Senate
  3. Passed House
  4. Conference
  5. To President
  6. Became Law

A bill to amend title XI of the Social Security Act to provide for the treatment of orphan drugs under the Medicare Drug Price Negotiation Program.

Sponsors

Sen. Peter Welch (D) sponsors S. 3019, and 2 members have co-sponsored it, all of them from the day it was introduced.

Committees

S. 3019 went before 1 committee: Finance.

Finance
Finance
Referred To · Oct 21, 2025 · 902 Bills

Actions

S. 3019 has taken 2 actions since Oct 21, 2025.

ChamberAction
Oct 21, 2025
Senate
Read twice and referred to the Committee on Finance.Finance Committee
Oct 21, 2025
Introduced in Senate

Votes

S. 3019 has not gone to a roll call.

Titles

S. 3019 goes by 3 titles, 1 of them short titles.

  • No Big Blockbuster Bailouts Act — Display Title
  • No Big Blockbuster Bailouts Act — Short Title(s) as Introduced
  • A bill to amend title XI of the Social Security Act to provide for the treatment of orphan drugs under the Medicare Drug Price Negotiation Program. — Official Title as Introduced

Lobbying

5 clients hired 5 firms and 27 registered lobbyists who named S. 3019 in 7 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Tariff (miscellaneous tariff bills), Pharmacy, Banking, Civil Rights/Civil Liberties.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
AMGEN INCDistrict of Columbia13
BRISTOL-MYERS SQUIBB COMPANYBiopharmaceutical CompanyNew Jersey11$60K
SOLENO THERAPEUTICS, INC.Soleno is focused on development of novel therapeutics for treatment of rare diseases.California11$20K
HARMONY BIOSCIENCESpharmaceuticalsPennsylvania11
PUBLIC CITIZENDistrict of Columbia11

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
AMGEN, INC.13
AVENUE SOLUTIONS11$60K
HARMONY BIOSCIENCES11
PUBLIC CITIZEN11
THE KPM GROUP DC LLC11$20K

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 27.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
AMGEN INCAMGEN, INC.2025 fourth_quarter$3.6M4th Quarter - Report
AMGEN INCAMGEN, INC.2026 first_quarter$2.6M1st Quarter - Report
AMGEN INCAMGEN, INC.2026 second_quarter$2.4M2nd Quarter - Report
HARMONY BIOSCIENCESHARMONY BIOSCIENCES2026 second_quarter$180K2nd Quarter - Report
PUBLIC CITIZENPUBLIC CITIZEN2025 fourth_quarter$73K4th Quarter - Report
BRISTOL-MYERS SQUIBB COMPANYAVENUE SOLUTIONS2026 second_quarter$60K2nd Quarter - Report
SOLENO THERAPEUTICS, INC.THE KPM GROUP DC LLC2026 first_quarter$20K1st Quarter - Report

Classification

The Congressional Research Service files S. 3019 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; S. 3019’s is Health.

s3019/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com